295 related articles for article (PubMed ID: 27006943)
1. Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review.
Kagota S; Maruyama K; McGuire JJ
Biomed Res Int; 2016; 2016():3130496. PubMed ID: 27006943
[TBL] [Abstract][Full Text] [Related]
2. Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism.
Lim J; Iyer A; Liu L; Suen JY; Lohman RJ; Seow V; Yau MK; Brown L; Fairlie DP
FASEB J; 2013 Dec; 27(12):4757-67. PubMed ID: 23964081
[TBL] [Abstract][Full Text] [Related]
3. Progression of Time-Dependent Changes to the Mechanisms of Vasodilation by Protease-Activated Receptor 2 in Metabolic Syndrome.
Maruyama K; McGuire JJ; Kagota S
Biol Pharm Bull; 2017; 40(12):2039-2044. PubMed ID: 29199228
[TBL] [Abstract][Full Text] [Related]
4. Age-related changes to vascular protease-activated receptor 2 in metabolic syndrome: a relationship between oxidative stress, receptor expression, and endothelium-dependent vasodilation.
Maruyama K; Kagota S; McGuire JJ; Wakuda H; Yoshikawa N; Nakamura K; Shinozuka K
Can J Physiol Pharmacol; 2017 Apr; 95(4):356-364. PubMed ID: 28103056
[TBL] [Abstract][Full Text] [Related]
5. Redox implications in adipose tissue (dys)function--A new look at old acquaintances.
Jankovic A; Korac A; Buzadzic B; Otasevic V; Stancic A; Daiber A; Korac B
Redox Biol; 2015 Dec; 6():19-32. PubMed ID: 26177468
[TBL] [Abstract][Full Text] [Related]
6. Activation of protease‑activated receptor‑2 is associated with increased expression of inflammatory factors in the adipose tissues of obese mice.
Li M; Yang X; Zhang Y; Chen L; Lu H; Li X; Yin L; Zhi X
Mol Med Rep; 2015 Oct; 12(4):6227-34. PubMed ID: 26252901
[TBL] [Abstract][Full Text] [Related]
7. Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models.
Singh H; Pragasam SJ; Venkatesan V
Endocr Metab Immune Disord Drug Targets; 2019; 19(4):481-489. PubMed ID: 30499422
[TBL] [Abstract][Full Text] [Related]
8. Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseases.
McGuire JJ
Curr Pharm Des; 2004; 10(22):2769-78. PubMed ID: 15320742
[TBL] [Abstract][Full Text] [Related]
9. Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.
Kagota S; Maruyama K; Wakuda H; McGuire JJ; Yoshikawa N; Nakamura K; Shinozuka K
Vascul Pharmacol; 2014 Oct; 63(1):46-54. PubMed ID: 25109437
[TBL] [Abstract][Full Text] [Related]
10. Toward drugs for protease-activated receptor 2 (PAR2).
Yau MK; Liu L; Fairlie DP
J Med Chem; 2013 Oct; 56(19):7477-97. PubMed ID: 23895492
[TBL] [Abstract][Full Text] [Related]
11. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction.
Gu P; Xu A
Rev Endocr Metab Disord; 2013 Mar; 14(1):49-58. PubMed ID: 23283583
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Nitric Oxide Synthase Activation via Protease-Activated Receptor 2 Is Involved in the Preserved Vasodilation in Aortas from Metabolic Syndrome Rats.
Maruyama K; Kagota S; McGuire JJ; Wakuda H; Yoshikawa N; Nakamura K; Shinozuka K
J Vasc Res; 2015; 52(4):232-43. PubMed ID: 26760532
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice.
Wang J; Chakrabarty S; Bui Q; Ruf W; Samad F
Am J Pathol; 2015 Feb; 185(2):524-35. PubMed ID: 25476527
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome.
Yamada Y; Takeuchi S; Yoneda M; Ito S; Sano Y; Nagasawa K; Matsuura N; Uchinaka A; Murohara T; Nagata K
Int J Cardiol; 2017 Aug; 240():332-338. PubMed ID: 28499669
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery.
Matsumoto T; Ishida K; Taguchi K; Kobayashi T; Kamata K
Peptides; 2009 Sep; 30(9):1729-34. PubMed ID: 19540892
[TBL] [Abstract][Full Text] [Related]
16. Inflammation, obesity, and thrombosis.
Samad F; Ruf W
Blood; 2013 Nov; 122(20):3415-22. PubMed ID: 24092932
[TBL] [Abstract][Full Text] [Related]
17. Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).
Yau MK; Lim J; Liu L; Fairlie DP
Expert Opin Ther Pat; 2016; 26(4):471-83. PubMed ID: 26936077
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress.
El-Daly M; Pulakazhi Venu VK; Saifeddine M; Mihara K; Kang S; Fedak PWM; Alston LA; Hirota SA; Ding H; Triggle CR; Hollenberg MD
Vascul Pharmacol; 2018 Oct; 109():56-71. PubMed ID: 29908295
[TBL] [Abstract][Full Text] [Related]
19. Protease-activated receptor 1 and 2 contribute to angiotensin II-induced activation of adventitial fibroblasts from rat aorta.
He RQ; Tang XF; Zhang BL; Li XD; Hong MN; Chen QZ; Han WQ; Gao PJ
Biochem Biophys Res Commun; 2016 Apr; 473(2):517-23. PubMed ID: 27012211
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin M in the development of metabolic syndrome and its potential as a novel therapeutic target.
Komori T; Morikawa Y
Anat Sci Int; 2018 Mar; 93(2):169-176. PubMed ID: 29103176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
